60.28

0.79% 0.47

After Hours: 60.39 0.11 +0.18%

Bristol Myers Squibb Co (BMY)

Overview News Price History Option Chain Financials Why BMY Down? Discussions Forecast Stock Split Dividend History

Bristol Myers Squibb Co stock is traded at $60.28, with a volume of 8.77M. It is up +0.79% in the last 24 hours and up +7.70% over the past month. Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Previous Close:

$59.81

Open:

$59.99

24h Volume:

8.77M

Relative Volume:

0.81

Market Cap:

$122.33B

Revenue:

$48.30B

Net Income/Loss:

$-8.95B

P/E Ratio:

-13.64

EPS:

-4.42

Net Cash Flow:

$13.94B

1W Performance:

+0.17%

1M Performance:

+7.70%

6M Performance:

+22.69%

1Y Performance:

+14.49%

1-Day Range:

$59.79

$60.76

1-Week Range:

$59.52

$63.33

52-Week Range:

$39.35

$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name

Bristol Myers Squibb Co

Sector

Healthcare (1169)

Industry

Drug Manufacturers - General (19)

Phone

(609) 252-4621

Address

ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY

Employee

34,100

Twitter

@BMSNEWS

Next Earnings Date

2024-10-31

Latest SEC Filings

BMY's Discussions on Twitter

Compare BMY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BMY Bristol Myers Squibb Co	60.28	122.33B	48.30B	-8.95B	13.94B	-4.42
LLY Lilly Eli Co	801.65	720.02B	45.04B	10.59B	414.30M	11.71
ABBV Abbvie Inc	211.55	373.46B	56.33B	4.28B	17.83B	2.40
JNJ Johnson Johnson	162.99	344.63B	88.82B	14.07B	18.06B	5.79
NVO Novo Nordisk Adr	75.89	336.88B	42.09B	14.65B	10.11B	3.2833
MRK Merck Co Inc	94.71	251.88B	64.17B	17.12B	18.10B	6.73

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-16-24	Upgrade	Jefferies	Hold → Buy
Dec-10-24	Resumed	BofA Securities	Neutral
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-25-24	Downgrade	Citigroup	Buy → Neutral
Oct-17-24	Initiated	Bernstein	Mkt Perform
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-09-23	Initiated	Deutsche Bank	Hold
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-20-23	Resumed	UBS	Neutral
Jul-14-23	Initiated	HSBC Securities	Reduce
Jul-10-23	Initiated	SVB Securities	Market Perform
Jun-28-23	Initiated	Daiwa Securities	Outperform
Mar-06-23	Initiated	Jefferies	Hold
Jan-17-23	Initiated	Cantor Fitzgerald	Overweight
Nov-18-22	Initiated	Credit Suisse	Neutral
Oct-10-22	Downgrade	Guggenheim	Buy → Neutral
Sep-14-22	Downgrade	Berenberg	Buy → Hold
Jun-03-22	Downgrade	Raymond James	Outperform → Mkt Perform
Apr-06-22	Resumed	Morgan Stanley	Underweight
Dec-17-21	Initiated	Goldman	Buy
Dec-09-21	Resumed	Wells Fargo	Equal Weight
Nov-19-21	Initiated	BMO Capital Markets	Outperform
Nov-01-21	Downgrade	Argus	Buy → Hold
Jul-27-21	Resumed	Truist	Buy
Apr-30-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-13-21	Upgrade	Truist	Hold → Buy
Nov-16-20	Upgrade	Societe Generale	Hold → Buy
Nov-10-20	Resumed	Bernstein	Mkt Perform
Nov-06-20	Downgrade	Gabelli & Co	Buy → Hold
Oct-19-20	Upgrade	Guggenheim	Neutral → Buy
Sep-29-20	Initiated	Berenberg	Buy
Jul-28-20	Initiated	Raymond James	Outperform
Apr-02-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-23-20	Downgrade	Societe Generale	Buy → Hold
Feb-27-20	Initiated	Barclays	Equal Weight
Jan-06-20	Resumed	Citigroup	Buy
Dec-13-19	Upgrade	Argus	Hold → Buy
Nov-22-19	Resumed	Morgan Stanley	Equal-Weight
Oct-17-19	Resumed	BofA/Merrill	Buy
Aug-14-19	Upgrade	Atlantic Equities	Neutral → Overweight
May-28-19	Initiated	Goldman	Buy
May-20-19	Downgrade	Argus	Buy → Hold
May-03-19	Upgrade	Barclays	Equal Weight → Overweight
May-03-19	Resumed	JP Morgan	Overweight
Jan-15-19	Upgrade	Societe Generale	Sell → Buy
Oct-22-18	Downgrade	Citigroup	Buy → Neutral

View All

Bristol Myers Squibb Co Stock (BMY) Latest News

Mar 13, 2025

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga

Mar 13, 2025

Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma

Mar 13, 2025

William Blair Issues Optimistic Estimate for BMY Earnings - Defense World

Mar 13, 2025

Mar 12, 2025

Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey

Mar 12, 2025

Bristol-Myers Squibb at Leerink Global Healthcare Conference: Pipeline Progress and Strategic Insights - Investing.com India

Mar 12, 2025

BMS $286m partner buy secures Abecma and closes chapter on bluebird - BioXconomy

Mar 12, 2025

Bristol Myers Squibb Acquires 2seventy bio for $286 Million - Lawyer Monthly Magazine

Mar 11, 2025

Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc. for approximately $280 million. - Marketscreener.com

Mar 11, 2025

Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc.. -March 10, 2025 - Marketscreener.com

Mar 11, 2025

Eaton's Bold Acquisition Moves Into Data Centers - Finimize

Mar 11, 2025

2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive

Mar 11, 2025

Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters.com

Mar 11, 2025

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal - Benzinga

Mar 11, 2025

Bristol Myers Squibb's Bold Move: Acquiring 2seventy Bio - Finimize

Mar 11, 2025

BMS Buys Abecma Partner 2seventy for $286M, Ending Cost Sharing Agreement - BioSpace

Mar 11, 2025

Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal (BMY:NYSE) - Seeking Alpha

Mar 11, 2025

Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal - MSN

Mar 11, 2025

Mar 10, 2025

Bristol Myers to acquire 2seventy bio for $286 million - Investing.com India

Mar 10, 2025

Bristol Myers to buy collaborator 2seventy bio for $286 mln By Investing.com - Investing.com South Africa

Mar 10, 2025

Bristol Myers to buy collaborator 2seventy bio for $286 mln - Investing.com

Mar 10, 2025

Bristol Myers Squibb Snaps Up 2seventy bio at 88% Premium: Major Biotech Acquisition - StockTitan

Mar 10, 2025

Bristol Myers to acquire 2seventy bio for $286 million By Investing.com - Investing.com UK

Mar 10, 2025

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb - Business Wire

Mar 10, 2025

Bristol Myers Stock Gains 9.2% in a Month: Should You Buy Now or Wait? - Nasdaq

Mar 10, 2025

#AAD25: What you need to know from Amgen, Bristol Myers, J&J and more - Endpoints News

Mar 10, 2025

Bristol-Myers Squibb Company (BMY): One of the Best Performing Dividend Stocks to Buy Now - Insider Monkey

Mar 10, 2025

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga

Mar 10, 2025

J&J, Protagonist's oral psoriasis prospect bests BMS' Sotyktu in pair of phase 3 trials - Fierce Biotech

Mar 10, 2025

Mar 09, 2025

Bristol-Myers Squibb (NYSE:BMY) Hits New 52-Week High – Here’s What Happened - Defense World

Mar 09, 2025

Mar 08, 2025

Is Bristol-Myers Squibb Company (BMY) The Best Cheap Dividend Stock To Buy Right Now? - Insider Monkey

Mar 08, 2025